Selenium as a Pleiotropic Agent for Medical Discovery and Drug Delivery
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 3764
Special Issue Editors
Interests: cancer theranostics; drug delivery; self-assembled biomaterials; multimodal imaging
Interests: tumor chemoradiotherapy; biomaterials and disease theranostics; signal transduction; oxidative stress and complex diseases
Interests: drug delivery; peptide-based nanoparticles; magnetic-propelled cell robots
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Selenium (Se) is an essential dietary trace nutriment for mammals, and the deficiency of selenium can cause cardiovascular disease, choric inflammation, infertility, cognitive decline, etc. In recent years, extensive evidence has shown that Se-containing agents, e.g., small molecule compounds, macromolecules, nanoparticles, and composite systems play an exclusively important role in the efficient therapy or prevention against cancer, Se-deficient chronic inflammation, cardiovascular disease, diabetes, fertility, and aging. On the other hand, the metabolism and cytotoxicity of Se at different statuses and forms in vivo have been widely investigated and discussed regarding the biosafety of Se. To expand the medical application of Se from bench to bedside, it is vital to discover pleiotropic Se reagents and Se-based delivery systems for achieving advanced therapeutic/preventative effects on various diseases. In particular, it is fundamentally important to study the mechanisms involved in Se-dependent therapeutic/preventative/toxic effects on different health outcomes in mammals. This Special Issue aims to report recent discoveries and mechanism studies of Se-based reagents or delivery systems for disease treatment or prevention, and recent progress in the mechanism studies on the Se-dependent metabolism and toxicity in mammals. In this regard, I would like to invite authors to contribute original papers and comprehensive reviews on the topic of Se-based pleiotropic reagents for advanced disease treatment or prevention.
Dr. Yanyu Huang
Dr. Cundong Fan
Dr. Zhaoqing Cong
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pleiotropic selenium reagents
- drug delivery
- disease treatment and prevention
- selenium metabolism
- selenium toxicity
